Globe Newswire (Tue, 10-Feb 7:30 AM ET)
Globe Newswire (Thu, 29-Jan 4:30 PM ET)
Globe Newswire (Wed, 17-Dec 7:30 AM ET)
Harvard Bioscience Schedules Q3 2025 Earnings Call: Investors Eye Upcoming November Update
Market Chameleon (Thu, 30-Oct 5:54 AM ET)
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, pharmaceutical and therapy discovery, bioproduction, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, and Panlab. The majority of its revenue comes from the United States.
Harvard Bioscience trades on the NASDAQ stock market under the symbol HBIO.
As of February 18, 2026, HBIO stock price declined to $0.59 with 234,756 million shares trading.
HBIO has a beta of 2.62, meaning it tends to be more sensitive to market movements. HBIO has a correlation of 0.21 to the broad based SPY ETF.
HBIO has a market cap of $26.38 million. This is considered a Sub-Micro Cap stock.
Last quarter Harvard Bioscience reported $21 million in Revenue and $.00 earnings per share. This beat revenue expectation by $591,000 and missed earnings estimates by -$.01.
In the last 3 years, HBIO traded as high as $6.29 and as low as $.28.
The top ETF exchange traded funds that HBIO belongs to (by Net Assets): VTI, VXF.
HBIO has underperformed the market in the last year with a return of -56.3%, while the SPY ETF gained +14.1%. In the last 3 month period, HBIO fell short of the market, returning -11.9%, while SPY returned +3.8%. However, in the most recent 2 weeks HBIO has outperformed the stock market by returning +18.0%, while SPY returned -0.1%.
HBIO support price is $.56 and resistance is $.63 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HBIO shares will trade within this expected range on the day.